RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms

RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms

Sarcoma

Ongoing, but not recruiting

1

Start Date 07/01/2009

Age of Trial (yrs) 14.8

Gleevec-resistant

IGF1R inhibitor + mTOR Inhibitor

Block related tumor signal paths

GIST not specified. GIST patient enrollment unknown.

09-091

Dana-Farber Cancer Institute Brigham and Women's Hospital Novartis Pfizer

Suzanne George, MD 617-632-5204 Richard Quek, MD richard_quek@dfci.harvard.edu

Oral Intravenous

The purpose of this research study is to determine the safety of the combination of RAD001 and CP-751,871, as well as the highest dose of this combination that can be given to people safely. RAD001 is a newly discovered drug that may stop cancer cells from growing abnormally. This drug has been extensively studied in many cancers. In particular, it has shown to be effective in slowing down the growth of kidney cancer. CP-751,871 is another newly discovered drug that may stop tumor growth. It is currently being studied in a wide variety of cancers, and information from those other research studies suggests that these two drugs in combination may help to stop cancer growth.